IL128124A0 - Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase - Google Patents

Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase

Info

Publication number
IL128124A0
IL128124A0 IL12812497A IL12812497A IL128124A0 IL 128124 A0 IL128124 A0 IL 128124A0 IL 12812497 A IL12812497 A IL 12812497A IL 12812497 A IL12812497 A IL 12812497A IL 128124 A0 IL128124 A0 IL 128124A0
Authority
IL
Israel
Prior art keywords
ribonucleotide reductase
components
directed against
antisense sequences
sequences directed
Prior art date
Application number
IL12812497A
Other languages
English (en)
Original Assignee
Genesense Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genesense Technologies Inc filed Critical Genesense Technologies Inc
Publication of IL128124A0 publication Critical patent/IL128124A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0093—Oxidoreductases (1.) acting on CH or CH2 groups (1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL12812497A 1996-08-02 1997-08-01 Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase IL128124A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2304096P 1996-08-02 1996-08-02
US3995997P 1997-03-07 1997-03-07
PCT/CA1997/000540 WO1998005769A2 (en) 1996-08-02 1997-08-01 Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase

Publications (1)

Publication Number Publication Date
IL128124A0 true IL128124A0 (en) 1999-11-30

Family

ID=26696655

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12812497A IL128124A0 (en) 1996-08-02 1997-08-01 Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
IL128124A IL128124A (en) 1996-08-02 1999-01-19 Antisense sequences and anti-cancer sequences directed against R1 and R2 components of ribonucleotide reductase

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL128124A IL128124A (en) 1996-08-02 1999-01-19 Antisense sequences and anti-cancer sequences directed against R1 and R2 components of ribonucleotide reductase

Country Status (12)

Country Link
US (1) US5998383A (xx)
EP (1) EP0917569B1 (xx)
JP (1) JP4301576B2 (xx)
CN (1) CN1189562C (xx)
AT (1) ATE309345T1 (xx)
AU (1) AU738592C (xx)
CA (1) CA2262776C (xx)
DE (1) DE69734589T2 (xx)
ES (1) ES2256893T3 (xx)
IL (2) IL128124A0 (xx)
NZ (1) NZ333802A (xx)
WO (1) WO1998005769A2 (xx)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
WO1998000532A2 (en) * 1996-07-01 1998-01-08 Wright Jim A Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth
US6593305B1 (en) 1996-08-02 2003-07-15 Genesense Technologies Inc. Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
JP2002501486A (ja) * 1997-03-19 2002-01-15 ジェネセンス・テクノロジーズ・インコーポレーテッド リボヌクレオチドレダクターゼｒ１を利用した悪性腫瘍の抑制
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
US6610539B1 (en) * 1997-07-10 2003-08-26 Genesense Technologies, Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
EP1584681A3 (en) * 1997-07-10 2005-11-09 GeneSense Technologies Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
JP4187413B2 (ja) * 1998-03-20 2008-11-26 コモンウェルス サイエンティフィック アンドインダストリアル リサーチ オーガナイゼーション 遺伝子発現の制御
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
WO2000044914A1 (en) * 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US6121000A (en) * 1999-02-11 2000-09-19 Genesense Technologies, Inc. Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
US20040138168A1 (en) * 1999-04-21 2004-07-15 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
US6642033B1 (en) * 1999-07-20 2003-11-04 V.I. Technologies, Inc. Nucleic acids for detecting parvovirus and methods of using same
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
CN1301816A (zh) * 1999-12-27 2001-07-04 上海博德基因开发有限公司 一种新的多肽——核苷酸还原酶10和编码这种多肽的多核苷酸
WO2001070949A1 (en) * 2000-03-17 2001-09-27 Benitec Australia Ltd Genetic silencing
EP1229134A3 (en) * 2001-01-31 2004-01-28 Nucleonics, Inc Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
DE10131148A1 (de) * 2001-06-28 2003-01-16 I P L Internat Pharmaceutics L Xenogene Oligo- oder/und Polyribonukleotide als Mittel zur Behandlung von malignen Tumoren
WO2004070033A1 (en) 2003-02-10 2004-08-19 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer
WO2004083432A1 (en) * 2003-03-21 2004-09-30 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
US20070274947A1 (en) * 2003-05-21 2007-11-29 Young Aiping H Antisense Oligonucleotides Directed to Ribonucleotide Reductase R1 and Uses Thereof in the Treatment of Cancer
WO2004106518A1 (en) * 2003-05-31 2004-12-09 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer
AU2004283294B2 (en) 2003-10-23 2011-03-17 Kineta Two, Llc Detection of mutations in a gene associated with resistance to viral infection, OAS1
US20080311126A1 (en) * 2004-01-12 2008-12-18 Genesense Technologies, Inc Antisense Oligonucleotides Directed to Ribonucleotide Reducatase R2 and Uses Thereof in Combination Therapies for the Treatment of Cancer
US8029815B2 (en) * 2004-04-28 2011-10-04 Elford Howard L Methods for treating or preventing restenosis and other vascular proliferative disorders
EP1784501B1 (en) * 2004-05-14 2015-11-18 Rosetta Genomics Ltd VIRAL AND VIRUS ASSOCIATED MicroRNAS AND USES THEREOF
US7968762B2 (en) * 2004-07-13 2011-06-28 Van Andel Research Institute Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
EP1786905B1 (en) * 2004-08-18 2011-08-03 Lorus Therapeutics Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
US20060185027A1 (en) * 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
TWI335352B (en) * 2005-03-31 2011-01-01 Calando Pharmaceuticals Inc Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
US9526707B2 (en) * 2007-08-13 2016-12-27 Howard L. Elford Methods for treating or preventing neuroinflammation or autoimmune diseases
US20100204305A1 (en) * 2007-12-11 2010-08-12 Lorus Therapeutics Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
PA8809001A1 (es) 2007-12-20 2009-07-23 Novartis Ag Compuestos organicos
WO2010027279A2 (en) * 2008-09-04 2010-03-11 Genesis Research And Development Corporation Limited Compositions and methods for the treatment and prevention of neoplastic disorders
US9289475B2 (en) 2008-11-06 2016-03-22 The Johns Hopkins University Treatment of chronic inflammatory respiratory disorders
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
EP3434772A3 (en) * 2010-10-18 2019-03-20 Arrowhead Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of rrm2 genes
KR101928116B1 (ko) 2011-01-31 2018-12-11 노파르티스 아게 신규 헤테로시클릭 유도체
CA2853256C (en) 2011-10-28 2019-05-14 Novartis Ag Novel purine derivatives and their use in the treatment of disease
SG11201406550QA (en) 2012-05-16 2014-11-27 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
KR20160095035A (ko) 2013-12-06 2016-08-10 노파르티스 아게 알파-이소형 선택성 포스파티딜이노시톨 3-키나제 억제제를 위한 투여 요법
CA3002954A1 (en) 2015-11-02 2017-05-11 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
EP0690869A1 (en) * 1993-03-23 1996-01-10 The Board Of Trustees Of The Leland Stanford Junior University Cellular regulation with riboregulators

Also Published As

Publication number Publication date
WO1998005769A2 (en) 1998-02-12
DE69734589T2 (de) 2006-08-10
EP0917569B1 (en) 2005-11-09
EP0917569A2 (en) 1999-05-26
AU738592C (en) 2002-07-25
ATE309345T1 (de) 2005-11-15
CN1231694A (zh) 1999-10-13
CA2262776A1 (en) 1998-02-12
DE69734589D1 (de) 2005-12-15
ES2256893T3 (es) 2006-07-16
AU3617597A (en) 1998-02-25
NZ333802A (en) 2001-09-28
JP2000517167A (ja) 2000-12-26
JP4301576B2 (ja) 2009-07-22
IL128124A (en) 2006-12-31
CN1189562C (zh) 2005-02-16
US5998383A (en) 1999-12-07
WO1998005769A3 (en) 1998-06-25
CA2262776C (en) 2005-03-08
AU738592B2 (en) 2001-09-20

Similar Documents

Publication Publication Date Title
IL128124A0 (en) Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
IL144975A0 (en) A composition containing an antisense oligonucleotide
HU9501963D0 (en) 7-deazapurine modified oligonucleotides
EP0977767A4 (en) AMINOOXY-MODIFIED OLIGONUCLEOTIDES
AU4595399A (en) Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues
IL128939A0 (en) Three component chimeric antisense oligonucleotides
EP1224266A4 (en) ENZYMES WITH LYSOSOMIAL TARGETING
IL134042A0 (en) Modified dorsal tissue affecting factor and compositions
AU6255896A (en) Triplex-forming antisense oligonucleotides having abasic lin kers targeting nucleic acids comprising mixed sequences of p urines and pyrimidines
AU5959396A (en) Antisense oligonucleotide modulation of raf gene expression
MX9804263A (es) Expresion de genes incrementada por intensificador en plantas.
EP1485401A4 (en) ANTISENSE THERAPY TRPM-2 USING AN OLIGONUCLEOTIDE HAVING 2'-O- (2-METHOXYL) ETHYL MODIFICATION
BR0008788A (pt) Sequencias anti-sentido antitumor dirigidas contra componentes r1 e r2 de ribonucleotìdeo reductase
WO1998000532A3 (en) Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
EP1123414A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF INTEGRIN ALPHA 4
AU8327798A (en) Antisense oligonucleotide sequences as inhibitors of microorganisms
WO2000029623A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO1994028176A3 (en) Bc200 rna, probes therefor and use thereof
WO1998040478A3 (en) Antisense inhibition of human stat-6
AU7425800A (en) Single stranded oligonucleotides, probes, primers and method for detecting spirochetes
WO2000029622A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
NZ507993A (en) Human deadenylating nuclease, its preparation and use
Abdula Silencing the code

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed